114 related articles for article (PubMed ID: 28154322)
21. Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2.
Zhou Y; Yamada N; Tanaka T; Hori T; Yokoyama S; Hayakawa Y; Yano S; Fukuoka J; Koizumi K; Saiki I; Sakurai H
Nat Commun; 2015 Jul; 6():7679. PubMed ID: 26158630
[TBL] [Abstract][Full Text] [Related]
22. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
23. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential.
Mao W; Irby R; Coppola D; Fu L; Wloch M; Turner J; Yu H; Garcia R; Jove R; Yeatman TJ
Oncogene; 1997 Dec; 15(25):3083-90. PubMed ID: 9444956
[TBL] [Abstract][Full Text] [Related]
24. ErbB receptors and signaling pathways in cancer.
Hynes NE; MacDonald G
Curr Opin Cell Biol; 2009 Apr; 21(2):177-84. PubMed ID: 19208461
[TBL] [Abstract][Full Text] [Related]
25. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
26. MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2.
Li H; Sun Q; Han B; Yu X; Hu B; Hu S
Int J Clin Exp Pathol; 2015; 8(5):4782-90. PubMed ID: 26191168
[TBL] [Abstract][Full Text] [Related]
27. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
28. 3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants.
Rahimi M; Huang KL; Tang CK
Cancer Lett; 2010 Sep; 295(1):59-68. PubMed ID: 20299148
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
30. A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer.
Gilmour AM; Abdulkhalek S; Cheng TS; Alghamdi F; Jayanth P; O'Shea LK; Geen O; Arvizu LA; Szewczuk MR
Cell Signal; 2013 Dec; 25(12):2587-603. PubMed ID: 23993964
[TBL] [Abstract][Full Text] [Related]
31. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.
Montero JC; Seoane S; Pandiella A
Cell Signal; 2013 Nov; 25(11):2281-9. PubMed ID: 23899556
[TBL] [Abstract][Full Text] [Related]
33. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
34. EphA2-dependent molecular targeting therapy for malignant tumors.
Biao-xue R; Xi-guang C; Shuan-ying Y; Wei L; Zong-juan M
Curr Cancer Drug Targets; 2011 Nov; 11(9):1082-97. PubMed ID: 21933105
[TBL] [Abstract][Full Text] [Related]
35. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
[TBL] [Abstract][Full Text] [Related]
36. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
38. Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis.
Cui XD; Lee MJ; Kim JH; Hao PP; Liu L; Yu GR; Kim DG
Hepatology; 2013 Jun; 57(6):2248-60. PubMed ID: 23315987
[TBL] [Abstract][Full Text] [Related]
39. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents.
Knebel A; Rahmsdorf HJ; Ullrich A; Herrlich P
EMBO J; 1996 Oct; 15(19):5314-25. PubMed ID: 8895576
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
